Patients with Graves’, Hashimoto’s Disease, vitiligo, and diabetes type 1 will be allowed (12) Have any immunodeficiency disease or immune-compromised state ( e.g. use of immunosuppressive agents) within 28 days of study treatment (13) Baseline coagulopathy > Grade 3 unless due to anticoagulant therapy (14) Peripheral neuropathy ≥ Grade 2 (15) Use of systemically-active steroi ds within 14 days of study tre atment (16) Use of more than 3 grams per day of acetaminophen (17) Use of aspirin or other nonsteroidal anti-inflammatory drugs fo r 2 days before, during, and for 2 days after each administration of pemetrexed disodium (5 days before, during, a nd 2 days after each administration of pemetrexed disodium for piroxicam, naproxen, diflunisal, or nab umetone) (18) Have received an investigational product within 2 8 days of study treatment (19) Have a known allergy to both penicillin and sulfa drugs (20) Have known or suspected allergy or hypersensitivity to yeast or any other component of CRS-207 (e.g. glycerol), Platinol or platinum-containing compounds, or pemetrexed (21) Have received a diagnosis of HIV, hepatitis B, or hepatitis C ( exception: clear evidence of natural immunity, immunity subsequent to vaccination, or successful eradication o f the virus following antiviral therapy) (22) Be a woman who is pregnant or breastfeeding (23) Have prosthetic heart valves; major implant(s) or device(s) (e. g. artificial joints and prosthetics) placed within 12 months of study screening; or current or prior history of infec tion or clinically significant adverse events (AEs) associated with an exogenous impla nt(s) or device(s) that canno t be easily removed (24) Have had major surgery or signif icant traumatic i njury occurring within 28 days prior to CRS-207 administration or anticipated surgery or procedure requiring general anesthesi a or deep sedation during study participation (including 28 days after last dose of CRS-207) (Minor procedure s [dental work, skin biopsy, etc.] celiac plexus block, and biliary stents are allowed.) Aduro Biotech, Inc. Protocol ADU-CL-02-v8 CRS-207 with Pemetrexed and Cisplatin STUDY SYNOPSIS (continued) Version 8, 08 March 2018 Page viii Name of Sponsor Company: Aduro Biotech, Inc. Individual Study Table Referring to Part of the Dossier Volume: Page: (For National Authority Use Only) Name of Finished Product: CRS-207; pemetrexed; cisplatin; cyclophosphamide Name of Active Ingredients: Pemetrexed: C 20H19N5Na2O6ꞏ7H 2O Cisplatin: PtCl 2H6N2 CRS-207: Lm ΔactA/ΔinlB /hMeso Cyclophosphamide (Cy): C7H15Cl2N2O2P•H 2O Exclusion criteria, continued: (25) Have an unhealed wound which incr eases risk for bacterial infection (26) Be unable to avoid intimate contact with another individual kno wn to be at high risk of listeriosis (e.g. newborn infant, pregnant female, etc.) f or at least 7 days after receiv ing a CRS-207 infusion (27) Have an intercurrent illness that is either life-threatening or of clinical significance such that it might limit compliance with study requirements (including, but not limited to, ongoing or active infection, metabolic (e.g.